Company / Shareholders' Equity
ImmunityBio, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$500.5M
FY2025
5-year range
-$587.0M / -$242.2M
FY2021-FY2025
Trend
-2.3%
vs FY2024
Sector context
#208 of 213
Health Care
What the data says
ImmunityBio, Inc. reports negative total equity of -$500M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$500M in FY2025.
Improved from -$587M to -$500M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 213This company -$500.5M Sector average $2.5B
▼
-119.6% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 2.3% year-over-year.
- Ranks #208 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$500.5M | -2.3% |
| FY2024 | -$489.1M | +16.7% |
| FY2023 | -$587.0M | -31.2% |
| FY2022 | -$447.3M | -84.7% |
| FY2021 | -$242.2M | -102.1% |
| FY2020 | -$119.8M | -199.3% |
| FY2019 | $120.7M | -58.9% |
| FY2018 | $293.4M | -17.6% |
| FY2017 | $356.0M | +518.1% |
| FY2016 | $57.6M | -83.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026